Want to see IN:RPGLIFE full AI Analyst Report?
RPGLIFE Stock Chart & Stats
₹2913.00
-₹8.90(-0.30%)
At close: 4:00 PM EDT
₹2913.00
-₹8.90(-0.30%)
Day’s Range― - ―
52-Week Range₹1,731.25 - ₹3,130.50
Previous CloseN/A
Volume16.15K
Average Volume (3M)1.52K
Market Cap
₹45.59B
Enterprise Value₹28.04B
Total Cash (Recent Filing)₹2.74B
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)38.2
Beta1.12
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.87%
Share Statistics
EPS (TTM)72.34
Shares Outstanding16,539,015
10 Day Avg. Volume1,057
30 Day Avg. Volume1,522
Financial Highlights & Ratios
PEG Ratio-0.72
Price to Book (P/B)5.08
Price to Sales (P/S)4.34
P/FCF Ratio-38.40K
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Very Low LeverageA conservatively positioned balance sheet gives RPG Life Sciences substantial financial flexibility and limits balance-sheet risk. Low leverage can support continued investment in branded formulations, help absorb earnings volatility, and reduce the burden of debt service over the next several quarters.
Resilient Revenue GrowthSustained revenue expansion indicates resilient demand for the company’s pharmaceutical formulations and provides a durable base for future earnings. Continued top-line growth can support operating scale, strengthen distribution reach, and preserve the company’s ability to reinvest in branded products.
Strong Historical Returns On EquityHistorically strong returns on equity suggest that RPG Life Sciences has converted its capital base into shareholder earnings efficiently. Although returns have recently eased, the multi-year record indicates an established earnings model and supports continued capital productivity if profitability stabilizes.
Bears Say
FY2026 Margin CompressionThe sharp FY2026 margin deterioration weakens the near-term quality and predictability of earnings, even though revenue continues to grow. If margins remain below prior levels, less revenue will convert into profit, limiting internal reinvestment capacity and reducing operating resilience.
Weaker Cash ConversionWeaker cash conversion means reported profitability is translating less effectively into available cash. Slightly negative free cash flow can constrain funding for product development, distribution, or capital needs and makes working-capital management more important over the next few quarters.
Sharp EPS DeclineThe pronounced decline in EPS signals that shareholder earnings have weakened materially despite positive revenue growth. This divergence indicates that recent operational or profitability pressures are affecting bottom-line performance, making sustained earnings recovery dependent on reversing the margin slowdown.
RPG Life Sciences Limited News
RPGLIFE FAQ
What was RPG Life Sciences Limited’s price range in the past 12 months?
RPG Life Sciences Limited lowest stock price was ₹1731.25 and its highest was ₹3130.50 in the past 12 months.
What is RPG Life Sciences Limited’s market cap?
RPG Life Sciences Limited’s market cap is ₹45.59B.
When is RPG Life Sciences Limited’s upcoming earnings report date?
RPG Life Sciences Limited’s upcoming earnings report date is Oct 29, 2026 which is in 2 days.
How were RPG Life Sciences Limited’s earnings last quarter?
RPG Life Sciences Limited released its earnings results on Jul 28, 2026. The company reported ₹18.598 earnings per share for the quarter.
Is RPG Life Sciences Limited overvalued?
According to Wall Street analysts RPG Life Sciences Limited’s price is currently Overvalued.
Does RPG Life Sciences Limited pay dividends?
RPG Life Sciences Limited pays a Notavailable dividend of ₹24 which represents an annual dividend yield of 0.87%. See more information on RPG Life Sciences Limited dividends here
What is RPG Life Sciences Limited’s EPS estimate?
RPG Life Sciences Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RPG Life Sciences Limited have?
RPG Life Sciences Limited has 16,539,015 shares outstanding.
What happened to RPG Life Sciences Limited’s price movement after its last earnings report?
RPG Life Sciences Limited reported an EPS of ₹18.598 in its last earnings report. Following the earnings report the stock price went down -1.283%.
Which hedge fund is a major shareholder of RPG Life Sciences Limited?
Currently, no hedge funds are holding shares in IN:RPGLIFE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RPG Life Sciences Limited
RPG Life Sciences Limited operates as a fully integrated pharmaceutical enterprise, engaged in the development, production, and commercialization of branded drug formulations, generic medications, and synthetic active pharmaceutical ingredients (APIs) for both the Indian and global markets. The company provides synthetic APIs for diverse medical applications, including immunosuppression, psychiatric conditions, cardiac health (anti-anginals), parasitic infections (anthelmentics), seizure management (anticonvulsants), and muscle spasm relief (antispasmodics). While its generics portfolio primarily centers on immunosuppressant treatments, its finished dosage formulations address a wide spectrum of therapeutic areas, such as nephrology, rheumatology, oncology, gastroenterology, cardiovascular health, diabetology, orthopedics, neuropsychiatry, and respiratory conditions, among many others. Established in 1968 with its headquarters in Mumbai, India, the company adopted its current name in February 2008, having previously been known as RPG Pharmaceuticals Limited. RPG Life Sciences Limited functions as a subsidiary of Nucleus Life Trust.
Technical Analysis
Bliss Gvs Pharma Limited
―
Hikal Limited
―
IOL Chemicals & Pharmaceuticals Ltd.
―
Solara Active Pharma Sciences Ltd.
―
Unichem Laboratories Limited
―